A cost-effectiveness analysis of lowering residential radon levels in Sweden —Results from a modelling study

Lung cancer is among the most fatal cancers with an estimated 5-year survival rate in the European Union of 13%. Globally it is estimated that lung cancer accounts for approximately 20% of all cancer deaths [1,2]. The economic burden of cancer, measured as the societal direct and indirect costs of cancer, is estimated to be around 1% of total Gross Domestic Product (GDP) in the European Union countries. Lung cancer is the most costly form of cancer and about 15% of the total cancer costs is attributed to lung cancer [3].
Source: Health Policy - Category: Health Management Authors: Source Type: research